While at the European Clinical Data Forum in Munich, Germany, we’ve learned that clinical trial challenges are no different on the other side of the pond. We’ve had the chance to share our solutions and hear new ideas about data integration and speeding drug time-to-market from some of the top pharmaceutical executives in the world.
At the conference, there’s been a focus on the CDISC and SDTM (Standard Data Tabulation Model) standard models and the role they play in outputting clinical trial information for proprietary and legacy data.
One of the companies that addressed this hot topic was our customer, Merck & Co. Company representative Travis Collopy provided insight on converting data from electronic data collection systems to the clinical data repository and the benefits of implementing STDM at the beginning of the process. He spoke about how this resulted in a standardized format that could be submitted to the FDA, an important step for all pharmaceutical companies.
We’ve had a great time on the tradeshow floor, and we’re excited to get back to the US with this new perspective on clinical trial standards. We’re looking forward to applying what we’ve learned to our data integration and harmonization services, so that we can better serve our national and international clients.
What do you consider to be the biggest similarities and differences between clinical trials in the US and Europe?
Until next time,